There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
週二，Longboard Pharmicals Inc（納斯達克股票代碼：LBPH）發佈了太平洋1b/2a期研究的主要數據，該研究評估了貝西卡色林（LP352）治療與各種發育和癲癇性腦病（DEE）相關的癲癇發作。
Cantor Fitzgerald writes that the data are among the best reported for seizure meds, with a median 53% reduction in seizures across subtypes (~33% placebo adjusted).
坎託·菲茨傑拉德寫道，這些數據是癲癇藥物報告的最佳數據之一，所有亞型的癲癇發作率中位數下降了53％（經安慰劑調整後約爲33％）。
Even though there were just four patients with Dravet Syndrome in the trial, the median seizure reduction achieved with bexicaserin was a remarkable 72%. This level of reduction is comparable to what UCB SA's (OTC: UCBJY) (OTC: UCBJF) Fintepla has demonstrated, a bar Cantor initially believed bexicaserin couldn't reach.
儘管試驗中只有四名德拉維特綜合徵患者，但使用貝西卡色林的發作中位數減少了驚人的72％。這種降低水平與UCB SA（場外交易代碼：UCBJY）（場外交易代碼：UCBJF）Fintepla所展示的水平相當，坎託最初認爲bexicaserin無法達到這一水平。
Cantor says "in light of these excellent results" that the price target for LBPH stock has been raised from $35 to $55, with an overweight rating.
坎託說，“鑑於這些優異的業績”，LBPH股票的目標股價已從35美元上調至55美元，評級爲增持。
Cantor notes that the increased price target might still prove highly conservative since it hasn't yet reflected the broad "DEE" opportunity in the model.
坎託指出，提高的目標股價可能仍非常保守，因爲它尚未反映出模型中廣泛的 “DEE” 機會。
The analyst awaits additional clarity on that path before incorporating.
在合併之前，分析師正在等待這條道路的進一步澄清。
The analyst lowered the discount rate from 14% to 12% and factored in less dilutive equity raises, given the stock action.
鑑於股票走勢，分析師將貼現率從14％下調至12％，並考慮了稀釋性較小的股權融資。
Cantor analyst notes LBPH remains a top pick - with even higher conviction now that the program is substantially derisked. The analyst sees peak bexicaserin sales of over $1 billion and potentially over $2 billion.
坎託分析師指出，LBPH仍然是首選——既然該計劃已大大降低風險，人們的信心甚至更高。分析師預計，貝西卡塞林的峯值銷售額將超過10億美元，可能超過20億美元。
Price Action: LBPH shares are up 222.60% at $19.45 on the last check Tuesday.
價格走勢：在週二的最後一次支票中，LBPH股價上漲222.60％，至19.45美元。
譯文內容由第三人軟體翻譯。